Merck Announces positive results for Gefapixant Phase 3 Trial to treat Chronic Cough Medical Dialogues Bureau21 March 2020 10:15 AM ISTKenilworth: Merck, known as MSD outside the United States and Canada, has announced top-line efficacy results from two ongoing pivotal Phase 3...